Compare · GLP-1 agonist
Orforglipron vs Retatrutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Orforglipron | Retatrutide | |
|---|---|---|
| Evidence | 9/10 | 7/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | An oral, non-peptide (small-molecule) GLP-1 receptor agonist, FDA-approved in April 2026 as Foundayo for chronic weight management. It is a once-daily pill with no food or timing restrictions — not a peptide, and not an injectable. | An investigational triple-hormone agonist with striking weight-loss data in trials, but not yet FDA-approved and with no peer-reviewed Phase 3 results. |
| Full profile → | Full profile → |
Orforglipron
Orforglipron (brand name Foundayo) belongs to the same drug family as semaglutide and tirzepatide — a group called GLP-1 receptor agonists (drugs that copy a natural gut hormone to curb appetite and steady blood sugar). But it has one big difference: it is a small molecule rather than a peptide (a…
Retatrutide
Retatrutide (Lilly's lab code LY3437943) is an experimental injectable drug being studied for obesity and type 2 diabetes. It has shown some of the biggest weight-loss numbers seen in any trial so far. But as of June 2026 it is not approved anywhere, and the big Phase 3 results that matter most…